Vontobel Holding Ltd. Has $2.04 Million Holdings in BioNTech SE (NASDAQ:BNTX)

Vontobel Holding Ltd. trimmed its position in shares of BioNTech SE (NASDAQ:BNTX) by 62.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 17,158 shares of the company’s stock after selling 28,574 shares during the period. Vontobel Holding Ltd.’s holdings in BioNTech were worth $2,038,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Candriam S.C.A. lifted its position in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the last quarter. Discovery Capital Management LLC CT bought a new position in shares of BioNTech in the second quarter worth about $2,467,000. Goldman Sachs Group Inc. lifted its holdings in shares of BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after acquiring an additional 26,777 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after purchasing an additional 24,426 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of BioNTech during the 1st quarter valued at approximately $703,000. 15.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BNTX shares. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. UBS Group boosted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $91.00 to $125.00 in a report on Monday, September 16th. HC Wainwright lifted their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Trading Down 2.4 %

NASDAQ:BNTX opened at $111.77 on Friday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The firm’s fifty day moving average is $104.56 and its 200-day moving average is $94.20. The firm has a market cap of $26.57 billion, a P/E ratio of 223.54 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the company posted ($0.86) EPS. The business’s revenue was down 23.3% compared to the same quarter last year. Equities analysts expect that BioNTech SE will post -3.04 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.